Which has higher valuation and earnings, DCGO or LFMD?

LifeMD has lower revenue, but higher earnings than DocGo. LifeMD is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.11 -$182.40M -$1.96 N/A LifeMD $194.05M 0.68 $14.35M -$0.05 N/A

Is DCGO or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% LifeMD 0.10% -168.23% -31.27%

Does the media prefer DCGO or LFMD?

In the previous week, DocGo had 3 more articles in the media than LifeMD. MarketBeat recorded 5 mentions for DocGo and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.67 beat DocGo's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DCGO or JYNT?

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 542.76%. Given DocGo's stronger consensus rating and higher possible upside, equities analysts plainly believe DocGo is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation & earnings, DCGO or JYNT?

Joint has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.11 -$182.40M -$1.96 N/A Joint $54.90M 1.88 $2.91M $0.27 26.96

Is DCGO or JYNT more profitable?

Joint has a net margin of 6.49% compared to DocGo's net margin of -65.29%. Joint's return on equity of 12.02% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% Joint 6.49% 12.02% 3.47%

Does the media favor DCGO or PARK?

In the previous week, DocGo had 3 more articles in the media than Park Dental Partners. MarketBeat recorded 5 mentions for DocGo and 2 mentions for Park Dental Partners. Park Dental Partners' average media sentiment score of 1.47 beat DocGo's score of 0.00 indicating that Park Dental Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Park Dental Partners 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, DCGO or PIII?

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.11 -$182.40M -$1.96 N/A P3 Health Partners $1.46B 0.03 -$147.95M -$33.00 N/A

Is DCGO or PIII more profitable?

P3 Health Partners has a net margin of -6.55% compared to DocGo's net margin of -65.29%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% P3 Health Partners -6.55% N/A -16.40%

Do analysts rate DCGO or PRPO?

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 542.76%. Given DocGo's stronger consensus rating and higher possible upside, research analysts clearly believe DocGo is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, DCGO or PRPO?

Precipio has lower revenue, but higher earnings than DocGo. Precipio is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.11 -$182.40M -$1.96 N/A Precipio $24.05M 1.72 -$360K -$0.64 N/A

Is DCGO or PRPO more profitable?

Precipio has a net margin of -4.47% compared to DocGo's net margin of -65.29%. Precipio's return on equity of -8.49% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% Precipio -4.47% -8.49% -5.75%

Does the media refer more to DCGO or PRPO?

In the previous week, DocGo had 3 more articles in the media than Precipio. MarketBeat recorded 5 mentions for DocGo and 2 mentions for Precipio. Precipio's average media sentiment score of 0.75 beat DocGo's score of 0.00 indicating that Precipio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precipio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DocGo (DCGO) Competitors

$0.36 0.00 (-1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$0.37 +0.00 (+1.10%)

As of 07:47 PM Eastern

Compare

DCGO vs. LFMD, JYNT, PARK, PIII, and PRPO

Should you buy DocGo stock or one of its competitors? DocGo's main competitors and comparable companies include LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), P3 Health Partners (PIII), and Precipio (PRPO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does DocGo compare to LifeMD?

DocGo (NASDAQ:DCGO) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

LifeMD has lower revenue, but higher earnings than DocGo. LifeMD is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
LifeMD	$194.05M	0.68	$14.35M	-$0.05	N/A

In the previous week, DocGo had 3 more articles in the media than LifeMD. MarketBeat recorded 5 mentions for DocGo and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.67 beat DocGo's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of DocGo shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
LifeMD	0.10%	-168.23%	-31.27%

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 542.76%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 176.33%. Given DocGo's higher possible upside, research analysts plainly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

DocGo has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market.

Summary

LifeMD beats DocGo on 9 of the 16 factors compared between the two stocks.

How does DocGo compare to Joint?

DocGo (NASDAQ:DCGO) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Joint has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
Joint	$54.90M	1.88	$2.91M	$0.27	26.96

In the previous week, DocGo had 5 more articles in the media than Joint. MarketBeat recorded 5 mentions for DocGo and 0 mentions for Joint. DocGo's average media sentiment score of 0.00 equaled Joint'saverage media sentiment score.

Company	Overall Sentiment
DocGo	Neutral
Joint	Neutral

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 542.76%. Given DocGo's stronger consensus rating and higher possible upside, equities analysts plainly believe DocGo is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

56.4% of DocGo shares are owned by institutional investors. Comparatively, 76.9% of Joint shares are owned by institutional investors. 5.1% of DocGo shares are owned by company insiders. Comparatively, 30.2% of Joint shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Joint has a net margin of 6.49% compared to DocGo's net margin of -65.29%. Joint's return on equity of 12.02% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Joint	6.49%	12.02%	3.47%

DocGo has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Joint has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Summary

Joint beats DocGo on 10 of the 15 factors compared between the two stocks.

How does DocGo compare to Park Dental Partners?

DocGo (NASDAQ:DCGO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Park Dental Partners has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
Park Dental Partners	$244.49M	0.39	-$360K	$1.05	18.90

DocGo presently has a consensus price target of $2.38, suggesting a potential upside of 542.76%. Park Dental Partners has a consensus price target of $28.50, suggesting a potential upside of 43.65%. Given DocGo's higher probable upside, research analysts clearly believe DocGo is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

56.4% of DocGo shares are held by institutional investors. 5.1% of DocGo shares are held by insiders. Comparatively, 10.6% of Park Dental Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Park Dental Partners has a net margin of 0.00% compared to DocGo's net margin of -65.29%. Park Dental Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Park Dental Partners	N/A	N/A	N/A

In the previous week, DocGo had 3 more articles in the media than Park Dental Partners. MarketBeat recorded 5 mentions for DocGo and 2 mentions for Park Dental Partners. Park Dental Partners' average media sentiment score of 1.47 beat DocGo's score of 0.00 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Park Dental Partners	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Park Dental Partners beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to P3 Health Partners?

DocGo (NASDAQ:DCGO) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

In the previous week, DocGo had 5 more articles in the media than P3 Health Partners. MarketBeat recorded 5 mentions for DocGo and 0 mentions for P3 Health Partners. DocGo's average media sentiment score of 0.00 equaled P3 Health Partners'average media sentiment score.

Company	Overall Sentiment
DocGo	Neutral
P3 Health Partners	Neutral

DocGo has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
P3 Health Partners	$1.46B	0.03	-$147.95M	-$33.00	N/A

DocGo currently has a consensus price target of $2.38, suggesting a potential upside of 542.76%. P3 Health Partners has a consensus price target of $17.00, suggesting a potential upside of 167.30%. Given DocGo's stronger consensus rating and higher possible upside, research analysts plainly believe DocGo is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

P3 Health Partners has a net margin of -6.55% compared to DocGo's net margin of -65.29%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
P3 Health Partners	-6.55%	N/A	-16.40%

56.4% of DocGo shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

DocGo beats P3 Health Partners on 8 of the 15 factors compared between the two stocks.

How does DocGo compare to Precipio?

DocGo (NASDAQ:DCGO) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, DocGo had 3 more articles in the media than Precipio. MarketBeat recorded 5 mentions for DocGo and 2 mentions for Precipio. Precipio's average media sentiment score of 0.75 beat DocGo's score of 0.00 indicating that Precipio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precipio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DocGo has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Precipio has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 542.76%. Given DocGo's stronger consensus rating and higher possible upside, research analysts clearly believe DocGo is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Precipio has lower revenue, but higher earnings than DocGo. Precipio is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
Precipio	$24.05M	1.72	-$360K	-$0.64	N/A

56.4% of DocGo shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 5.1% of DocGo shares are owned by company insiders. Comparatively, 16.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Precipio has a net margin of -4.47% compared to DocGo's net margin of -65.29%. Precipio's return on equity of -8.49% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Precipio	-4.47%	-8.49%	-5.75%

Summary

Precipio beats DocGo on 9 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.55M	$9.68B	$7.14B	$13.26B
Dividend Yield	N/A	2.61%	2.53%	17.34%
P/E Ratio	-0.19	34.20	274.32	26.20
Price / Sales	0.11	4.90	618.16	93.09
Price / Cash	6.68	22.82	27.22	34.70
Price / Book	0.29	5.20	11.23	6.40
Net Income	-$182.40M	$315.68M	$3.49B	$381.07M
7 Day Performance	N/A	-1.41%	-1.68%	-0.65%
1 Month Performance	-9.36%	-2.64%	-5.97%	-4.51%
1 Year Performance	-71.26%	8.89%	8.11%	1.82%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	2.7978 of 5 stars	$0.37 -1.2%	$2.38 +550.7%	-70.9%	$36.55M	$322.20M	N/A	3,568	News Coverage
LFMD LifeMD	3.1923 of 5 stars	$2.74 -3.9%	$7.57 +176.3%	-60.7%	$132.07M	$194.05M	N/A	384	Gap Up
JYNT Joint	1.724 of 5 stars	$7.28 -2.5%	N/A	-19.8%	$105.65M	$58.55M	26.96	330
PARK Park Dental Partners	4.0953 of 5 stars	$19.84 -1.3%	$28.50 +43.6%	N/A	$94.34M	$251.37M	18.90	1,212
PIII P3 Health Partners	2.0039 of 5 stars	$6.36 +1.4%	$17.00 +167.3%	-26.5%	$46.17M	$1.46B	N/A	320

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors